Results 91 to 100 of about 33,756 (203)
A cyclooxygenase-2 (COX-2) inhibitor celecoxib has been previously reported to have cytotoxic activities towards gastric, prostate, ovarian, colon and breast cancer cell lines.
Enade Perdana Istyastono +2 more
doaj +1 more source
Purpose To evaluate the comparative effectiveness of intra‐articular platelet‐rich plasma (PRP), stromal vascular fraction (SVF), bone marrow aspirate concentrate (BMAC), umbilical cord‐derived mesenchymal stem cell (UC‐MSC), and hyaluronic acid (HA) for pain relief and functional improvement in patients with knee osteoarthritis through network meta ...
Joo Hyung Han +5 more
wiley +1 more source
Network pharmacology and molecular docking identify a coordinated dual‐axis regulatory framework for Yueju pill in Hashimoto's thyroiditis. Candidate compounds and prioritized targets converge on TNF–NF‐κB inflammatory and PI3K–Akt survival/apoptosis signaling, providing computational support for a testable multi‐target hypothesis requiring ...
Hao Zhang, Kuojun Ren, Shengying Wang
wiley +1 more source
Optimasi Pembentukan Multikomponen Kristal Celecoxib-Piperin [PDF]
Celecoxib merupakan obat golongan NSAID yang bekerja secara spesifik menghambat enzim siklooksigenase-2. Senyawa ini termasuk ke dalam BCS kelas II karena memiliki kelarutan yang rendah dan permeabilitas yang tinggi.
Fauziyyah, Dirfedli
core +1 more source
IntroductionIntestinal ischemia/reperfusion (I/R) injury is associated with high mortality and there is an unmet need for novel therapies. The intestinal expression of cyclooxygenase-2 (COX-2) increases rapidly after mesenteric I/R, but it is still a ...
Szilvia B. László +17 more
doaj +1 more source
The immunosuppressive in OM Staphylococcus aureus employs multiple physical barriers to evade host immunity during skeletal infection, including biofilm formation on implant surfaces and necrotic bone tissues, invasion into the osteocyte lacuno‐canalicular network (OLCN), intracellular persistence within osteoblasts, osteoclasts, and osteocytes, and ...
Qingqiang Lei +7 more
wiley +1 more source
William L Pridgen,1 Carol Duffy,2 Judy F Gendreau,3 R Michael Gendreau3 1Innovative Med Concepts, LLC, 2Department of Biological Sciences, University of Alabama, Tuscaloosa, AL, 3Gendreau Consulting, LLC, Poway, CA, USA Objective: Infections and other ...
Gendreau RM +11 more
core +1 more source
Safety of Nonsteroidal Anti‐Inflammatory Drug Use in Traumatic Brain Injury
ABSTRACT Background Use of nonsteroidal anti‐inflammatory drugs (NSAIDs) after a traumatic brain injury (TBI) is controversial due to potential worsening of an intracranial hemorrhage (ICH). This study evaluated if NSAID use within 14 days of TBI was associated with a clinically significant progression of intracranial bleed (PIB).
Jennifer Beavers +10 more
wiley +1 more source
ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Mareena Biju +6 more
wiley +1 more source
Revealing Changes in Celecoxib Nanostructured Lipid Carrier’s Bioavailability Using Hyaluronic Acid as an Enhancer by HPLC-MS/MS [PDF]
Yi Zhu,1,2,* Meiling Chen,3,* Chuangzan Yang,1,2 Geng Lu,1,2 Sa Huang,1,2 Meili Chen,3 Yufei Wang,4 Junfeng Ban1– 3 1Guangdong Pharmaceutical University, Guangzhou, People’s Republic of China; 2The Innovation Team for Integrating Pharmacy with ...
Huang S +6 more
core

